K
KINIKSA PHARMACEUTICALS LTD
NASDAQ: KNSA (Kiniksa Pharmaceuticals, Ltd.)
Last update: 4 hours ago35.43
-0.34 (-0.95%)
| Previous Close | 35.77 |
| Open | 35.57 |
| Volume | 225,878 |
| Avg. Volume (3M) | 707,085 |
| Market Cap | 2,625,634,560 |
| Price / Earnings (TTM) | 708.60 |
| Price / Sales | 4.99 |
| Price / Book | 5.30 |
| 52 Weeks Range | |
| Earnings Date | 29 Jul 2025 |
| Profit Margin | -3.52% |
| Operating Margin (TTM) | 9.63% |
| Diluted EPS (TTM) | -0.240 |
| Quarterly Revenue Growth (YOY) | 72.50% |
| Total Debt/Equity (MRQ) | 2.17% |
| Current Ratio (MRQ) | 3.66 |
| Operating Cash Flow (TTM) | 44.03 M |
| Levered Free Cash Flow (TTM) | 25.15 M |
| Return on Assets (TTM) | -1.77% |
| Return on Equity (TTM) | -3.81% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Drug Manufacturers - Specialty & Generic (US) | Bullish | Mixed |
| Drug Manufacturers - Specialty & Generic (Global) | Bullish | Mixed | |
| Stock | Kiniksa Pharmaceuticals, Ltd. | Bullish | Bullish |
AIStockmoo Score
0.6
| Analyst Consensus | 3.0 |
| Insider Activity | -3.5 |
| Price Volatility | -3.0 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | 4.0 |
| Average | 0.60 |
|
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and mavrilimumab. |
|
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Investment Style | Small Growth |
| % Held by Insiders | 3.80% |
| % Held by Institutions | 97.31% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 54.00 (Jefferies, 52.41%) | Buy |
| Median | 48.00 (35.48%) | |
| Low | 42.00 (Wells Fargo, 18.54%) | Buy |
| Average | 48.00 (35.48%) | |
| Total | 2 Buy | |
| Avg. Price @ Call | 29.59 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Jefferies | 29 Jul 2025 | 54.00 (52.41%) | Buy | 30.37 |
| Wells Fargo | 09 Jul 2025 | 42.00 (18.54%) | Buy | 28.80 |
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| MOAT ROSS | - | 35.51 | -3,523 | -125,102 |
| TESSARI EBEN | - | 35.93 | -115,060 | -4,105,678 |
| Aggregate Net Quantity | -118,583 | |||
| Aggregate Net Value ($) | -4,230,780 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | 35.82 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| TESSARI EBEN | Officer | 15 Sep 2025 | Automatic sell (-) | 16,400 | 36.56 | 599,584 |
| TESSARI EBEN | Officer | 15 Sep 2025 | Option execute | 6,500 | - | - |
| TESSARI EBEN | Officer | 05 Sep 2025 | Automatic sell (-) | 13,389 | 35.71 | 478,121 |
| TESSARI EBEN | Officer | 05 Sep 2025 | Option execute | 13,389 | - | - |
| MOAT ROSS | Officer | 04 Sep 2025 | Automatic sell (-) | 3,523 | 35.51 | 125,102 |
| TESSARI EBEN | Officer | 04 Sep 2025 | Automatic sell (-) | 85,271 | 35.51 | 3,027,973 |
| TESSARI EBEN | Officer | 04 Sep 2025 | Option execute | 85,271 | - | - |
| Date | Type | Details |
|---|---|---|
| 28 Aug 2025 | Announcement | Kiniksa Pharmaceuticals to Present at Upcoming Investor Conferences |
| 29 Jul 2025 | Announcement | Kiniksa Pharmaceuticals Reports Second Quarter 2025 Financial Results and Recent Portfolio Execution |
| 24 Jul 2025 | Announcement | Kiniksa Pharmaceuticals to Report Second Quarter 2025 Financial Results on July 29, 2025 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |